StockNews.AI
AMGN
StockNews.AI
113 days

AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS

1. Amgen will report Q1 2025 results on May 1, 2025. 2. Conference call with CEO Robert A. Bradway will follow the announcement. 3. Amgen's innovative pipeline continues to advance in various disease areas. 4. Recognized as a top innovative company and best employer in 2024. 5. Amgen is part of the Dow Jones and Nasdaq-100 indices.

Earnings
+1.93%Current Return
VS
+0.62%S&P 500
$283.0904/28 04:16 PM EDTEvent Start
$288.5604/29 11:02 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report may not significantly surprise markets but could reflect stability.

How important is it?

Investors closely watch earnings; stable results could maintain investor confidence but market expectations are already tempered.

Why Short Term?

The earnings report will directly affect AMGN's stock in the immediate future.

Related Companies

AMGNBRK.BJNJ
, /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.  In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.  For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, TikTok, YouTube and Threads.  CONTACT: Amgen, Thousand OaksElissa Snook, 609-251-1407 (media) Justin Claeys, 805-313-9775 (investors) SOURCE Amgen WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News